Join
Live feed
·
PRReleasevia Quantisnow
MaxCyte Inc. logo

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

ByQuantisnow·Wall Street's wire, on your screen.
MXCT· MaxCyte Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MXCT (MaxCyte Inc.) and more on Quantisnow.